You are hereAugust 1, 2017
What’s the Stem Cells Buzz this Week? - Stem Cells for Corneal Wound Healing, Reprogramming Leukemic Cells, Marketing of High-Cost Regenerative Medicine, and Predicting Effects of MSCs on SLE!
The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!
Reviewing Stem Cells for Corneal Wound Healing
Wound healing in the cornea in response to injury or surgery represents a complex process governed by various types of stem cells. A recent review article in STEM CELLS from the lab of Alexander V. Ljubimov (Cedars-Sinai Medical Center, Los Angeles, USA) now presents, for the first time, the available evidence on stem cell participation in corneal wound healing. Furthermore, Saghizadeh et al. report on significant studies regarding the generation of corneal stem cells from pluripotent stem cells (among notable other cell sources) and their applicability to wound healing.
Tales from Reprograming Leukemic Cells to Pluripotency
A brief report from the laboratory of Mickie Bhatia (McMaster University, Hamilton, Ontario, Canada) tells of his team’s recent efforts in the generation of induced pluripotent stem cells (iPSCs) from leukemic cells as a modeling tool. In a STEM CELLS brief report,Lee et al. reveal that reprogramming in acute myeloid leukemia (AML) cells is a rare event that only occurs in those cells without genomic aberrations. Therefore, leukemic cells may suffer from an inherent “blockage” that prevents the attainment of the pluripotent state.
How to Plan Ahead in the Marketing of High Cost Regenerative Medicine
A review from the lab of Richard T. Maziarz (Oregon Health and Science University, Portland, Oregon, USA), published in STEM CELLS Translational Medicine brings us something different this week. In their words, “The development of cellular therapies faces a series of regulatory obstacles. Often overlooked will be barriers to utilization based upon reimbursement issues, practice guidelines, and payer contract restrictions. The authors provide guidance for early planning of reimbursement strategies to be performed by the cellular therapy biotechnology industry to assure successful launches within the U.S. multi-payer as well as the European Union members single-payer systems.” Sounds like a fascinating read!
Predicting the Effect of MSC Treatment in SLE Patients
A new study from the lab of Lingyun Sun (Nanjing University Medical School, China) aimed to identify possible serum markers to predict the therapeutic effect of mesenchymal stem cells (MSCs) in the treatment of systemic lupus erythematosus (SLE). In STEM CELLS Translational Medicine, Wang et al. report that high levels of IFN-γ indicated a good clinical response to MSCs transplantation when followed-up for one year.
That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!